This week, the biotechnology company that is revolutionising agriculture by equipping crops with genetic defences against disease, has announced that its Series A funding has been finally closed at $10.3m, oversubscribed from the original $8.1m.
The round was led by Corteva through its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S (managed by Future Planet Capital), SynBioVen, and AgFunder. The final close brings Resurrect Bio’s total capital raised to approximately $12.4M since founding, including its 2023 seed round.
The oversubscription is a strong signal of confidence in Resurrect Bio’s approach to durable crop protection and in the urgent need for sustainable, gene-edited disease resistance. Momentum behind the round follows Resurrect Bio’s joint development agreement with Corteva, announced in March 2026, to develop disease-resistance in corn.
The funds will be deployed to scale Resurrect Bio‘s three core capabilities:
- Its FloraFold® AI in-silico discovery platform, which predicts interactions between the plant and pathogen proteins
- Its high-throughput functional biology platform, which validates those predictions at scale
- Its Resurrection platform, which reactivates cryptic resistance mechanisms already present in elite germplasm.
Together, these platforms dramatically compress the timeline from discovery to deployment in crop. With this capital in place and a growing team behind it, Resurrect Bio is now fully ready to engage seed companies and breeders through additional joint development agreements, bringing durable disease-resistance traits to commercial pipelines faster than conventional breeding can achieve.
Dr. Cian Duggan, CEO, said, “We’re proud to have closed this round with such a distinguished and strategically aligned group of partners. The strength of this raise reflects a growing conviction in what we’re building – a scalable, AI-driven platform for resurrecting disease resistance in the world’s most important crops. It’s also a validation of what’s possible when you combine the UK’s world-class plant science base with commercial ambition to translate it into real-world impact. We’re expanding our team, deepening our platforms and actively seeking joint development agreements with seed companies and breeders who want to bring durable resistance traits to farmers.”
